Bullish Case: ABCL’s IV surface is high and wingy, yet the Helium–market uncertainty gap is mostly negative near the near-term strikes (market pricing more vol than Helium expects). The return surface’s densest likelihood cells cluster around modest positive outcomes for ~0–2y holds. With recent mean-reverting price action and a fresh business catalyst tail risk rather than a confirmed shock, a grind-up with realized vol < implied looks most plausible.

Bearish Case: A falsifiable bearish path is an idiosyncratic biotech disappointment (trial/regulatory/safety) that flips realized volatility above implied. In that case the ABCL downside wing on the IV surface would “stay rich” or re-richen, invalidating the compression implied by the negative Helium–market gap. The return surface still contains meaningful probability mass for -15% to -45% outcomes, especially if SPY sells off.

Potential Outcomes:

1. +3%→+10% (40%): ABCL remains mean-reverting; Helium–market IV gap stays negative → vol compression.
2. -8%→+8% (30%): no decisive headline; ABCL trades within the return-surface high-likelihood band.
3. +12%→+20% (15%): deal/partner momentum sustains; SPY stable and ABCL call demand persists.
4. -15%→-30% (10%): downside headline; IV reprices upward vs Helium (gap turns positive).
5. -30%→-45% (5%): ABCL shock amplified by SPY drawdown/vol expansion.

Trading Oracle: Sign Up to access trading oracle trade ideas.

June 23, 2026